-
公开(公告)号:NO20014535D0
公开(公告)日:2001-09-18
申请号:NO20014535
申请日:2001-09-18
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL C , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:AT432074T
公开(公告)日:2009-06-15
申请号:AT03815258
申请日:2003-12-30
Applicant: VERTEX PHARMA
Inventor: SAUNDERS JEFFREY , MIKNIS GREGORY F , BLAKE JAMES
IPC: A61K31/433 , A61P35/00 , A61P37/00 , C07D285/10 , C07D417/06 , C07D417/12
Abstract: The present invention relates to novel phosphate isosteres. The invention relates to compounds having a sulfhydantoin or a reverse sulfhydantoin moiety, uses thereof, and related methods. The present invention relates to compounds of formula I or II: or pharmaceutically acceptable salts thereof; wherein Q, T, m, and X are as described herein. These compounds are inhibitors of phosphatases, particularly inhibitors of SHP-2. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing these compounds and compositions in the treatment of various phosphatase-mediated diseases.
-
公开(公告)号:PL350911A1
公开(公告)日:2003-02-10
申请号:PL35091100
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , C07C275/34
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:HU0201214A2
公开(公告)日:2002-08-28
申请号:HU0201214
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: BADIA MICHAEL C , BETHIEL SCOTT , SAUNDERS JEFFREY , STAMOS DEAN , TRUDEAU MARTIN
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.
-
公开(公告)号:CA2367017A1
公开(公告)日:2000-09-28
申请号:CA2367017
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: BADIA MICHAEL , SAUNDERS JEFFREY , TRUDEAU MARTIN , STAMOS DEAN , BETHIEL SCOTT
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , A61K31/277 , C07C275/34
Abstract: The present invention relates to compounds which inhibit IMPDH. This inventi on also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
-
公开(公告)号:AP813A
公开(公告)日:2000-02-28
申请号:AP9700973
申请日:1997-04-23
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID , BADIA MICHAEL C , BEMIS GUY , BETHIEL RANDY S , FRANK CATHRINE A , NOVAK PERRY M , RONKIN STEVEN M , SAUNDERS JEFFREY
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C275/00 , A61
Abstract: A class of compounds which are IMPDH inhibitors, and pharmaceutical compositions comprising these compounds, of the formula: A is selected from (Ci-C6) alkyl, or (C2-C6)- alkenyl or alkynyl; B is a monocyclic or bicyclic ring system, D is selected from C(O), C(S), or S(0)2.
-
公开(公告)号:CZ301802B6
公开(公告)日:2010-06-30
申请号:CZ20013349
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07C275/34 , C07D307/20 , A61K31/17 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/00 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: Rešení se týká derivátu mocoviny vzorce 181 a 169, které inhibují IMPDH, a farmaceutických prostredku, které je obsahují. Používají se jako terapeutická cinidla pro procesy zprostredkovávané IMPDH, napríklad pri odmítání transplantátu, reakci štepu vuci hostiteli nebo autoimunitním onemocnení.
-
公开(公告)号:BG64507B1
公开(公告)日:2005-05-31
申请号:BG10294598
申请日:1998-11-23
Applicant: VERTEX PHARMA
Inventor: ARMISTEAD DAVID , BADIA MICHAEL , BEMIS GUY , BETHIEL RANDY , FRANK CATHARINE , NOVAK PERRY , RONKIN STEVEN , SAUNDERS JEFFREY
IPC: A61K31/17 , A61K31/18 , A61K31/404 , A61K31/42 , A61K31/421 , A61K31/422 , A61P9/14 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/06 , A61P43/00 , C07C275/42 , C07D263/18 , C07D263/32 , C07D277/18 , C07D413/12 , C07C275/28 , C07C275/34
Abstract: The invention relates to a new class of compounds which are inhibitors of IMPDH enzyme activity. The have the formula where A, D and B have the meanings listed in the description. The invention also relates to pharmaceutical compositions containing these compounds and to methods for IMPDH activity inhibition by using them.
-
公开(公告)号:GEP20033130B
公开(公告)日:2003-07-10
申请号:GEAP2000004561
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , BADIA MICHAEL , SAUNDERS JEFFREY , RONKIN STIVEN
IPC: C07C275/40 , C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653
Abstract: 1. Technical Result Obtaining new compounds inhibiting IMPDH. 2. Essence The present invention relates to compounds, which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds. 3. Field of Application Medicine.
-
公开(公告)号:AR029341A1
公开(公告)日:2003-06-25
申请号:ARP000101205
申请日:2000-03-17
Applicant: VERTEX PHARMA
Inventor: STAMOS DEAN , TRUDEAU MARTIN , BETHIEL SCOTT , RONKIN STEVEN M , BADIA MICHAEL , SAUNDERS JEFFREY
IPC: C07D307/20 , A61K31/27 , A61K31/275 , A61K31/341 , A61K31/421 , A61K31/422 , A61K31/454 , A61K31/5377 , A61K31/541 , A61K45/00 , A61P1/18 , A61P9/10 , A61P11/06 , A61P19/02 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/02 , A61P43/00 , C07C275/40 , C07C275/42 , C07D263/32 , C07D413/12 , C07D417/12 , C07F9/653 , C07C275/34 , A61K31/277 , A61P37/00
Abstract: Un compuesto inhibidor de la enzima IMPDH que tiene, la formula (A) en donde: cada uno de r1 y R2 es seleccionado independientemente entre hidrogeno; -CF3; -[alquilo(C1-6) de cadena recta o ramificada]; -[alquilo(C1-6) de cadena recta o ramificada]-R7; -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]; -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-R7 o ûR7; y en donde al menos uno de R1 o R2 es û[alquilo (C1-6) de cadena recto o ramificada]ûR7; -[alquenilo (c2-6) o alquinilo (C2-6) de cadena recto o ramificada]ûR7 o ûR7 en donde hasta 4 átomos de hidrogeno en cualquiera de dichos alquilo, alquenilo o alquinilo son opcionalmente e independientemente reemplazados por R3; y en donde uno o ambos de R1 o R2 son esterificados opcionalmente para formar una prodroga; o en donde R1 y R2 alternativamente forman conjuntamente tetrahidrofuranilo, en donde R9 es hidrogeno, (R)-metilo, (R)-etilo o (R)-hidroximetilo, un átomo de hidrogeno en dicho tetrahidrofurano es reemplazado por ûOR6 o ûR7 y en donde R9 es (S)ûmetilo, (S)-etilo o (S)-hidroximetilo , un átomo de hidrogeno en dicho tetrahidrofurano es reemplazado opcionalmente por ûOR6 o -R7, en donde si R9 es hidrogeno, (R)-metilo, (R)-etilo o (R)-hidroximetilo y cada uno de R1 y R2 son independientemente hidrogeno, -[alquilo(C1-6) no sustituido de cadena recta o ramificada], o -[alquenilo(C2-6) o alquinilo (C2-6) no sustituidos de cadena recta o ramificada], entonces la porcion del compuesto representada por ûCH(R1)R2 es un alquilo (C5-12), alquenilo (C5-12) o alquinilo (C5-12) de cadenas rectas o ramificadas; cada R3 es seleccionado independientemente entre halo, CH, -OR4 o ûN(R5)2; R4 es seleccionado entre hidrogeno, -[alquilo(C1-6) de cadena recta o ramificada], -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], [alquilo (C2-6) de cadena recta o ramificada]-R7, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-R7, -C(O)-[alquilo (C1-6) de cadena recta o ramificada] ûC(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -C(O)-[alquilo(C1-6) de cadena recta o ramificada]-N(R8)2, -C(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-N(R8)2, -P(O)(OR8)2, -P(O)(OR8)(R8), -C(O)-R7, -S(O)2N(R5)2, -[alquilo(C1-6) de cadena recta o ramificada]ûCN, o -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-CN; Cada R5 es seleccionado independientemente entre hidrogeno, -[alquilo (C1-6) de cadena recta o ramificada], -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -[alquilo (C1-6) de cadena recta o ramificada]-R7, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada ]-R7, -[alquilo (C1-6) de cadena recta o ramificada] ûR7, -[alquilo (C1-6) de cadena recta o ramificada]ûCN, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]-CN, -[alquilo(C1-6) de cadena recta o ramificada]-OR4, -[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada]ûOR4, -C(O)-[alquilo (C1-6) de cadena recta o ramificada], -C(O)-[alquenilo (C2-6) o alquinilo (C2-6) de cadena recta o ramificada], -C(O)-R7, -C(O)O-R7,-C(O)O- [alquilo(C1-6) de cadena recta o ramificada], -C(O)O-[alquenilo(C2-6) o alquinilo(C2-6) de cadena recta o ramificada], -S(O)2-[alquilo(C1-6) de cadena recta o ramificada], o ûS(O)2-R7; o dos porciones R5, si están ligados al mismo átomo de nitrogeno, forman conjuntamente con dicho átomo de nitrogeno un anillo heterocíclico de 3 a 7 miembros, en donde dicho anillo heterocíclico contiene opcionalmente 1 a 3 heteroátomos adicionales seleccionados independientemente de N; O, S, S(O)2; R6 es seleccionado entre ûC(O)-CH3, CH2-C(O)-OH, -CH2-C(O)-O-tBu, -CH2-CN o CH2-CsCH; cada R7 es un sistema anular monocíclico o bicíclico, en donde en dicho sistema anular: i) cada anillo comprende 3 a 7 átomos en el anillo seleccionado independientemente entre C, N, O o S; ii) no más de 4 átomos del anillo son seleccionados entre N, O o S; iii) cualquier CH2 es reemplazado opcionalmente con C(O); iv) cualquier S es reemplazado opcionalmente con S(O) o S(O)2; cada R8 es seleccionado independientemente entre hidrogeno o û [alquilo(C1-4) de cadena o ramificada]; en donde en cualquier sistema anular en dicho compuesto hasta 3 átomos de hidrogeno ligados a los átomos del anillo son reemplazados opcionalmente e independientemente con halo, hidroxi, nitro, ciano, amino, -[alquilo (C1-4) de cadena recta o ramificada]; o-[alquilo (C1-4) de cadena recta o ramificada], -[alquenilo (C2-4) o alquinilo (C2-4) de cadena recta o ramificada], o O-[alquenilo(C2-6) o alquinilo (C2-4) de cadena recata o ramificada]; y en donde cualquier sistema anular es opcionalmente benzofusionado; R9 es seleccionado entre hidrogeno, (R)-metilo, (S)-metilo, (R)-etilo, (S)ûetilo, (R)-hidroximetilo o (S)-hidroximetilo; R10 es seleccionado entre ûCsN o 5 oxazolilo; y R11 es seleccionado entre halo, -O-[alquilo (C1-3) de cadena recta o ramificada] o ûO-[alquenilo (C2-3) o alquinilo(C2-3) de cadena recta o ramificada].
-
-
-
-
-
-
-
-
-